Lexaria Bioscience stock has been a major dip these last 5 days. On July 15 the stock price was $7.07, then it started to plunge exponentially. On July 19 the stock sank to the price of $6.26. It surged back up leaving with the price of $6.43. As of the last trading session the stock has been rising by 4.27%. The market capitalization of Lexaria Bioscience equals $33.
638 million VIRAL-A20-3, which is the Company’s Phase 3 clinical study for the development of its drug delivery platform, has been successfully completed. Colchicine is an approved drug that is used to treat a variety of inflammatory conditions It is the effects of dehydraTECH or control colchicine on the rodent’s total drug also used to reduce the effects of SARS-CoV-2 and COVID-19. Similar to other known antiviral agents, the bioavailability of oral colchicine has diminished in humans. According to the company, this drug can improve its safety and efficacy.
Colchicine has a narrow therapeutic index, which means it has a high level of toxic content. This means it could be used to reduce overall dosing requirements while maintaining therapeutic levels. The VIRAL-A20-3 study was performed in Sprague-Dawley rats to evaluate delivery. The study also assessed the maximum concentration of drug that was delivered to the bloodstream.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.